Sky News has learnt that Evaro, which offers next-day prescription services for contraceptive and sexual health products as well as scores of minor conditions, has landed an injection of capital from investors led by AlbionVC.
The Series A round is also being backed by Simplyhealth Ventures, Exceptional Ventures, Cornerstone VC and BBI.
Evaro has partnerships with Clue, a period-tracking app, and Lovehoney, a sexual wellness retailer Lovehoney.
Money latest: Criminal barrister talks about ‘painfully low’ salaries
The company’s new funding will accelerate its healthcare-as-a-service model in three core areas: consumer brands seeking new revenue streams; healthcare organisations expanding digital capacity, and employers offering health benefits to their workforces.
Evaro says it helps alleviate pressure on the NHS at a time of lengthy waiting lists for appointments and treatment.
“When a third of people are waiting over a week just to see their GP, it’s time to think through alternative solutions that help people get the care they need while supporting NHS capacity,” said Dr Thuria Wenbar, Evaro co-founder and chief executive.
“We’re making healthcare as accessible as online banking, and this funding lets us prove that model works at scale.”
The company was founded in 2018 by Dr Wenbar and husband Oskar.
“We’ve seen embedded finance transform banking, and Evaro is now driving the embedded health revolution,” said Christoph Ruedig, partner at AlbionVC and new Evaro board member.
“This now allows consumer brands to enter the healthcare space safely, unlocking massive latent demand while relieving pressure on the NHS.”
Evaro, which did not disclose its new valuation, said it aimed to serve 10 million patients over the next three years.
